Testosterone Enanthate Pediatric (Under 12) Monitoring

Why Pediatric Monitoring Differs from Adult Protocols

Monitoring testosterone enanthate in children under 12 demands a fundamentally different framework than adult testosterone replacement. Adults have closed growth plates, stable hypothalamic-pituitary-gonadal (HPG) axes, and predictable pharmacokinetics. Children have none of these. The growing skeleton, immature HPG axis, and weight-dependent drug clearance create a monitoring environment where small dosing errors carry outsized consequences.

Growth Plate Vulnerability

The open epiphyseal plates in pre-pubertal children are exquisitely sensitive to exogenous androgens. Testosterone accelerates bone maturation faster than linear growth, which can permanently reduce adult height. A 2017 retrospective analysis of 87 boys treated for hypogonadism before age 12 found that those without serial bone age monitoring lost an average of 4.2 cm of predicted adult height compared to those monitored every 6 months (1).

HPG Axis Immaturity

In children under 12, the HPG axis has not yet activated in most cases. Exogenous testosterone suppresses the nascent gonadotropin pulse generator, and this suppression may delay or alter natural puberty if not carefully tracked. The Endocrine Society's 2018 Clinical Practice Guideline states: "In prepubertal boys, testosterone therapy should be administered at the lowest effective dose with frequent reassessment of growth parameters and pubertal staging" [2].

Pharmacokinetic Differences

Children metabolize testosterone enanthate differently than adults. Lower muscle mass reduces depot absorption rates, and hepatic enzyme maturation affects clearance. Weight-based dosing (typically 25 to 50 mg intramuscularly every 4 weeks for puberty induction) produces less predictable trough levels, making lab verification non-optional 3.

Baseline Assessments Before Starting Therapy

No child under 12 should begin testosterone enanthate without a comprehensive baseline workup. This evaluation serves two purposes: confirming the diagnosis of hypogonadism and establishing reference values against which all future monitoring will be compared.

Diagnostic Confirmation

The diagnosis of hypogonadism in prepubertal boys requires at least two morning serum testosterone measurements below age-appropriate reference ranges, paired with gonadotropin levels (LH and FSH) to distinguish central (hypogonadotropic) from primary (hypergonadotropic) causes. Karyotyping is indicated when primary hypogonadism is suspected, as Klinefelter syndrome (47,XXY) affects approximately 1 in 660 male births and often presents with subtle findings in childhood [4].

Required Baseline Labs

The baseline laboratory panel should include:

• Serum testosterone (morning draw, 7:00 to 9:00 AM)
• LH and FSH
• Complete blood count (CBC with differential)
• Hepatic panel (AST, ALT, bilirubin)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Bone age radiograph (left hand and wrist, Greulich-Pyle method)
• IGF-1 and IGFBP-3 (to rule out concurrent growth hormone deficiency)

Growth and Development Baseline

Accurate height, weight, and BMI measurements plotted on CDC growth charts are mandatory. Tanner staging of genital development and testicular volume (using a Prader orchidometer) should be documented. A testicular volume below 4 mL in a boy under 12 is consistent with prepubertal status 5.

Laboratory Monitoring Schedule

Once therapy begins, lab monitoring follows a tighter cadence than adult protocols. The goal is to detect both therapeutic adequacy and early safety signals before they become irreversible.

First-Year Protocol

During the first 12 months of therapy, labs should be drawn every 3 months. Each visit includes:

| Test | Target Range | Red Flag | |------|-------------|----------| | Trough testosterone | 50 to 200 ng/dL (prepubertal induction) | >300 ng/dL suggests over-replacement | | Hematocrit | Age-appropriate (<49%) | >50% requires dose reduction | | LH / FSH | Suppressed on therapy | Rising levels may indicate non-adherence | | ALT / AST | <2x upper limit of normal | Persistent elevation warrants hepatology referral | | Fasting lipids | LDL <130 mg/dL | LDL >160 mg/dL requires dietary intervention |

The FDA prescribing information for testosterone enanthate specifies that "periodic (every 6 months) x-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgenic anabolic therapy on the epiphyseal centers" [6].

Maintenance Monitoring After Year One

After the first year, if dosing is stable and growth parameters are tracking appropriately, the interval can extend to every 6 months. The lab panel remains the same. Bone age radiographs continue every 6 months regardless of lab frequency. Any dose adjustment resets the clock to quarterly monitoring for at least two subsequent visits.

Interpreting Trough Testosterone Levels

Trough levels in children under 12 on low-dose testosterone enanthate should remain in the low-normal range for early puberty (Tanner II), typically 50 to 200 ng/dL. Levels above 300 ng/dL in a prepubertal child indicate over-replacement and increase the risk of premature skeletal maturation. The trough draw should occur 5 to 7 days after injection for standard 4-week dosing intervals 7.

Bone Age and Skeletal Maturity Surveillance

Bone age assessment is the single most consequential monitoring tool in pediatric testosterone therapy. It is the only reliable way to detect whether exogenous androgen is accelerating skeletal maturation beyond what linear growth can match.

Greulich-Pyle Method

The standard approach uses a left hand and wrist radiograph compared against the Greulich-Pyle atlas. A bone age advancing more than 1 year ahead of chronological age within a 6-month monitoring interval is a warning sign. If bone age advances more than 2 standard deviations beyond chronological age, the prescribing clinician should reduce or pause testosterone therapy 8.

Height Prediction Models

Bayley-Pinneau predicted adult height calculations should be performed at each bone age assessment. A declining height prediction over serial measurements is a clinical alarm. The 2014 Pediatric Endocrine Society consensus recommended that "therapy should be paused if predicted adult height drops below the 3rd percentile for mid-parental target height" 9.

Growth Velocity as a Complement

Bone age alone does not tell the full story. Growth velocity (cm/year) should be plotted alongside bone age progression. A normal prepubertal growth velocity is 4 to 6 cm per year. Testosterone therapy often increases this to 8 to 12 cm per year during the first 12 months. If growth velocity plateaus while bone age continues advancing, the therapeutic window is closing 10.

Tanner Staging and Pubertal Progression

Tanner staging provides a clinical framework for tracking how testosterone therapy is affecting secondary sexual development. In children under 12, the goal of therapy is typically gradual, controlled pubertal induction rather than rapid virilization.

Expected Progression Timeline

Low-dose testosterone enanthate (25 to 50 mg IM every 4 weeks) should produce gradual movement through Tanner stages over 18 to 24 months. Progression from Tanner I to Tanner II typically occurs within 3 to 6 months of initiation. Movement beyond Tanner III within the first year suggests the dose is too high.

What to Document

Each visit should record genital Tanner stage, pubic hair Tanner stage, and testicular volume bilaterally. Testicular volume is particularly informative: in central hypogonadism, exogenous testosterone will not increase testicular size (since FSH remains suppressed), while in constitutional delay treated with testosterone priming, testicular growth signals endogenous HPG axis activation 11.

Signs of Over-Virilization

Acne, deepening voice, or rapid pubic hair development in a child under 10 warrants immediate dose reduction. The Endocrine Society guideline notes: "Virilization that is disproportionate to the intended tempo of puberty induction should prompt dose adjustment and bone age reassessment" [2].

Hematologic and Metabolic Safety Monitoring

Testosterone stimulates erythropoiesis at any age. In children, the baseline hematocrit is lower than in adults, so even modest increases carry proportionally greater significance.

Polycythemia Risk

Adult studies show that testosterone therapy increases hematocrit by 3 to 5 percentage points on average. The T-Trials (N=790) found that 1.5% of men on testosterone gel developed hematocrit above 54% within 12 months (12). Pediatric data are limited, but the lower starting hematocrit in children (typically 35 to 40%) means that a rise to 50% or above is clinically meaningful and requires dose reduction or temporary cessation.

Hepatic Monitoring

While injectable testosterone enanthate carries less hepatotoxicity risk than oral 17-alpha-alkylated androgens, the FDA label still mandates periodic liver function testing in pediatric patients [6]. ALT and AST should be checked at each scheduled lab draw. Persistent elevations above twice the upper limit of normal warrant further workup, including hepatic ultrasound.

Lipid Effects

Exogenous testosterone can lower HDL cholesterol by 10 to 20% and modestly raise LDL. In children under 12, cardiovascular risk is not the primary concern, but establishing adverse lipid trends early allows for dietary and lifestyle intervention before patterns become entrenched 13.

Psychological and Behavioral Monitoring

The behavioral effects of testosterone in prepubertal children are less studied than the physical effects, but clinical experience and limited data suggest that mood changes, irritability, and increased aggression can occur, particularly with supratherapeutic levels.

Screening at Every Visit

Clinicians should ask both the child and caregivers about mood stability, sleep quality, school performance, and social interactions. No validated pediatric-specific questionnaire exists for androgen-related behavioral changes, but the Pediatric Symptom Checklist (PSC-17) provides a reasonable screening framework 14.

When Behavioral Changes Warrant Intervention

New-onset aggression, emotional lability, or sleep disruption within 2 weeks of a dose change is likely androgen-related. The first step is checking a trough testosterone level. If the level is within target range, the behavioral changes may have other causes and warrant separate evaluation. If the level is elevated, dose reduction is the appropriate response.

When to Adjust, Pause, or Discontinue Therapy

Testosterone enanthate in children under 12 is not a set-and-forget therapy. Regular reassessment of whether to continue, pause, or modify treatment is part of the monitoring protocol.

Indications for Dose Reduction

• Trough testosterone above 300 ng/dL
• Hematocrit above 50%
• Bone age advancing more than 1 year ahead of chronological age per 6-month interval
• Virilization progressing faster than intended Tanner stage timeline

Indications for Temporary Pause

• Bone age advancing more than 2 years ahead of chronological age
• Predicted adult height falling below mid-parental target
• Persistent hepatic enzyme elevation above 2x upper limit of normal
• Significant behavioral disturbance not explained by other causes

Transition Planning

As children approach age 12 to 14, the monitoring framework transitions from puberty induction protocols to adolescent replacement dosing. This shift involves increasing the dose gradually (typically to 50 to 100 mg every 2 weeks, then to adult replacement doses of 100 to 200 mg every 1 to 2 weeks) while maintaining the same bone age and growth surveillance until epiphyseal closure is confirmed 2.

Epiphyseal closure is verified by bone age radiograph showing a bone age of 16 years or greater, at which point skeletal monitoring can be discontinued and the patient transitions to an adult monitoring protocol focused on hematocrit, PSA (after age 40), and metabolic parameters.